Biontech Se Intrinsic Value Calculation – BIONTECH SE’s Total Revenue Drops 74.0% in Q3 FY 2023
November 19, 2023
🌥️Earnings Overview
For the third quarter of Fiscal Year 2023, ending September 30 2023, BIONTECH SE ($NASDAQ:BNTX) reported total revenue of EUR 0.9 billion, which was a 74.0% decrease compared to the corresponding period of the previous year. Net income for the same quarter was EUR 0.16 billion, a decrease of 91.0% from the same quarter last year.
Analysis – Biontech Se Intrinsic Value Calculation
GoodWhale’s analysis of BIONTECH SE‘s financials provides insight into the intrinsic value of BIONTECH SE’s share. Using our proprietary Valuation Line, we estimate the intrinsic value of BIONTECH SE’s stock to be around $310.4. This is significantly higher than its current market price of $99.7, indicating that the stock is undervalued by a whopping 67.9%. This presents a great opportunity for investors to buy BIONTECH SE’s stock at an attractive discount. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biontech Se. More…
| Total Revenues | Net Income | Net Margin |
| 6.62k | 2.75k | 45.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biontech Se. More…
| Operations | Investing | Financing |
| 5.35k | -4.42k | -830.4 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biontech Se. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 22.21k | 2.34k | 82.86 |
Key Ratios Snapshot
Some of the financial key ratios for Biontech Se are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 242.4% | – | 55.9% |
| FCF Margin | ROE | ROA |
| 70.9% | 11.6% | 10.4% |
Peers
The company’s products include the BNT162 program, which is based on its proprietary mRNA technology platform, and the INO-4800 program, which is based on its CRISPR/Cas9 platform. BioNTech SE has collaborations with several companies, including Inhibitor Therapeutics Inc, Amplia Therapeutics Ltd, Pharmicell Co Ltd, to develop and commercialize its products.
– Inhibitor Therapeutics Inc ($OTCPK:INTI)
Inhibitor Therapeutics Inc is a clinical stage biopharmaceutical company developing drugs to treat cancer. The company’s most advanced product candidate is ITI-214, which is in Phase 1/2 clinical trials for the treatment of solid tumors. ITI-214 is a small molecule inhibitor of the PI3K/mTOR pathway.
– Amplia Therapeutics Ltd ($ASX:ATX)
Founded in 2016, Amplia Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel, next-generation therapies for patients with cancer and other serious diseases. The company’s lead product candidate, AMP-224, is a first-in-class, orally-available small molecule inhibitor of the polo-like kinase 1 (PLK1) enzyme. PLK1 is a known oncogene that is overexpressed in a wide variety of solid tumors and hematologic malignancies, and is associated with tumor progression, metastasis, and resistance to standard-of-care treatments. In preclinical studies, AMP-224 has demonstrated potent anti-tumor activity as a single agent and in combination with other anti-cancer agents. Amplia is currently evaluating AMP-224 in an ongoing Phase 1 clinical trial in patients with advanced solid tumors.
With a market cap of 19.21M as of 2022, Amplia Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel, next-generation therapies for patients with cancer and other serious diseases. The company’s lead product candidate, AMP-224, is a first-in-class, orally-available small molecule inhibitor of the polo-like kinase 1 (PLK1) enzyme. PLK1 is a known oncogene that is overexpressed in a wide variety of solid tumors and hematologic malignancies, and is associated with tumor progression, metastasis, and resistance to standard-of-care treatments. In preclinical studies, AMP-224 has demonstrated potent anti-tumor activity as a single agent and in combination with other anti-cancer agents. Amplia is currently evaluating AMP-224 in an ongoing Phase 1 clinical trial in patients with advanced solid tumors.
– Pharmicell Co Ltd ($KOSE:005690)
Pharmicell Co Ltd is a South Korean pharmaceutical company with a market cap of 612.04B as of 2022. The company has a Return on Equity of 10.65%. Pharmicell is a leading manufacturer of cell culture media and reagents, with a focus on providing products for stem cell research. The company also offers a range of other products and services, including contract research and development, and custom manufacturing.
Summary
With total revenue of EUR 0.9 billion, there was a 74.0% decrease compared to the same period last year. Net income was also down 91.0% from the same time the previous year to EUR 0.16 billion. Despite the underperformance, the stock price rose on the news, indicating the market is still confident in the long term prospects of the company. Investors should keep a close eye on the company’s performance, as the pandemic continues to challenge the global economy.
Related Posts
Recent Posts
